Diagnostic Biomarker Candidates Proposed Using Targeted Lipid Metabolomics Analysis of the Plasma of Patients with PDAC
Cancers · 12.09.2025 · 17 (18) · 2988
DOI: 10.3390/cancers17182988 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 12.09.2025. Verfasst von Sung-Sik Han und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang 10408, Republic of Korea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, National Cancer Center, National Cancer Center of Korea.
Abstract (Originalsprache)
Background/Objectives: We recently discovered that tumors rely on blood fatty acids as an energy source for growth. Therefore, we investigated biomarkers in the lipid fractions of plasma from patients with pancreatic ductal adenocarcinoma (PDAC) for the screening diagnosis of PDAC.
Methods
We screened common fatty acid types in human (normal 99, PDAC 103) and mouse (normal 7, KPC 22) plasma samples using a non-targeted approach. Subsequently, we identified targets in human plasma (set A: normal 68, PC 102) that could distinguish between healthy individuals and patients with cancer. Next, we verified whether the identified targets were useful in a new human set (set B: 96 normal, 78 PC). We combined sets A and B to create set C and further divided it into a training set (7:3 ratio; normal 115, pancreatic cancer 126) and a validation set (normal 49, PC 54). The identified targets were used to train three statistical models (logistic regression (LR), random forest (RF), and support vector machine (SVM) with a radial basis function (RBF) kernel).
Results
The comparison of human and mouse plasma identified eight common lipid metabolites. We further identified four platforms containing these metabolites for target analysis: acylcarnitines, phospholipids, fatty acid amides, and sphingolipids. We analyzed the four platforms using sets A, B, and C and found 20 lipids (1 acylcarnitine, 1 sphingolipid, and 18 phospholipids) that met the criterion of AUC ≥ 0.75 in all three sets. Based on an average AUC for LR models with 11 or more phospholipids, the separation performance between healthy individuals and patients with cancer was 0.9207 (sensitivity, 90.74%; specificity, 86.22%; PPV, 87.90%; NPV, 89.42%), and the AUC of the validation set for CA19-9 in the same groups was 0.7354. The addition of CA19-9 to the LR models resulted in a separation performance of 0.9427 (90.74%; 88.01%; 89.32%; 89.61%) for the validation set.
Conclusions
We identified 18 candidate fatty acid metabolites that could serve as biological markers in the serum lipid fractions of pancreatic cancer patients and confirmed that all of them decreased in patients. Additionally, we developed an algorithm utilizing these markers, which demonstrated a 25% increase in discriminatory power compared to the AUC value of CA19-9, an FDA-approved biomarker for pancreatic cancer. In summary, we identified candidate metabolites and algorithms that could serve as biomarkers in the lipid fractions of plasma from patients with pancreatic cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang 10408, Republic of Korea.
- Research Institute, National Cancer Center, Goyang 10408, Republic of Korea.
- Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang 10408, Republic of Korea.
- Department of Convergence Medicine, Department of Digital Medicine, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
- Proteomics Core Facility, Research Core Center, Research Institute, National Cancer Center, Goyang 10408, Republic of Korea.
- Biopharmaceutical Chemistry Major, Department of Applied Chemistry, School of Science and Technology, Kookmin University, Seoul 02707, Republic of Korea.
ORCID-Profile: Sang Myung Woo, Woo Jin Lee, Jung Won Chun, Hyun Ju Yoo, Soo-Youl Kim
Förderung
- National Research Foundation of Korea
- National Cancer Center
- National Cancer Center of Korea
Zitieren
APA
Han, S. S., Woo, S. M., Lee, J. H., Kang, J. H., Park, S. J., Lee, W. J., Park, H. M., Chun, J. W., Kim, S. J., Yoo, H. J., Kim, K. H., & Kim, S. Y. (2025). Diagnostic Biomarker Candidates Proposed Using Targeted Lipid Metabolomics Analysis of the Plasma of Patients with PDAC. Cancers, 17(18), 2988. https://doi.org/10.3390/cancers17182988
Vancouver
Han SS, Woo SM, Lee JH, Kang JH, Park SJ, Lee WJ, et al. Diagnostic Biomarker Candidates Proposed Using Targeted Lipid Metabolomics Analysis of the Plasma of Patients with PDAC. Cancers. 2025;17(18):2988. doi:10.3390/cancers17182988
BibTeX
@article{Han2025,
author = {Han, Sung-Sik and Woo, Sang Myung and Lee, Jun Hwa and Kang, Joon Hee and Park, Sang-Jae and Lee, Woo Jin and Park, Hyeong Min and Chun, Jung Won and Kim, Su Jung and Yoo, Hyun Ju and Kim, Kyung-Hee and Kim, Soo-Youl},
title = {Diagnostic Biomarker Candidates Proposed Using Targeted Lipid Metabolomics Analysis of the Plasma of Patients with PDAC},
journal = {Cancers},
year = {2025},
volume = {17},
number = {18},
pages = {2988},
doi = {10.3390/cancers17182988}
}
EUVIMED